A Phase I/II Study Combining Erlotinib and Dasatinib for Non-Small Cell Lung Cancer

BACKGROUND. EGFR and Src are frequently activated in non-small cell lung cancer (NSCLC). In preclinical models, combining EGFR and Src inhibition has additive synergistic effects. We conducted a phase I/II trial of the combination of Src inhibitor dasatinib with EGFR inhibitor erlotinib to determine...

पूर्ण विवरण

में बचाया:
ग्रंथसूची विवरण
मुख्य लेखकों: Gold, Kathryn A., Lee, J. Jack, Harun, Nusrat, Tang, Ximing, Price, Justina, Kawedia, Jitesh D., Tran, Hai T., Erasmus, Jeremy J., Blumenschein, George R., William, William N., Wistuba, Ignacio I., Johnson, Faye M.
स्वरूप: Artigo
भाषा:Inglês
प्रकाशित: AlphaMed Press 2014
विषय:
Clinical Trial Results
ऑनलाइन पहुंच:https://ncbi.nlm.nih.gov/pmc/articles/PMC4201000/
https://ncbi.nlm.nih.gov/pubmed/25170013
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2014-0228
टैग : टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!

समान संसाधन